October 17, 2019

Teneobio and Selexis Expand Relationship with Three Commercial License Agreements for Multi-specific Antibody Candidates in Oncology

Read More
September 17, 2019

Generium Launches First Biosimilar of Dornase Alfa; Becomes Sixth Approved Product Using Selexis SUREtechnology Platform

Read More
September 05, 2019

ZyVersa Therapeutics to Advance Development of Its Lead Inflammasome Inhibitor with Selexis and KBI Biopharma’s Integrated Development Platform

Read More
June 20, 2019

Avacta and Selexis Partner to Develop Cell Line for Clinical Manufacturing

Read More
May 06, 2019

Selexis to Present Data at ESACT 2019 from the SUREtechnology and Beacon® Optofluidic Collaboration

Read More